Zobrazeno 1 - 10
of 254
pro vyhledávání: '"M. Nachury"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
A Buisson, M Serrero, R Altwegg, T Guilmoteau, G Bouguen, M Nachury, A Amiot, L Vuitton, X Treton, L Caillo, B Pereira, M Fumery
Publikováno v:
Journal of Crohn's and Colitis
Journal of Crohn's and Colitis, 2023, 17 (Supplement_1), pp.i707-i707. ⟨10.1093/ecco-jcc/jjac190.0709⟩
Journal of Crohn's and Colitis, 2023, 17 (Supplement_1), pp.i707-i707. ⟨10.1093/ecco-jcc/jjac190.0709⟩
Background We aimed to compare the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis (UC) previously exposed to at least one anti-TNF agent. Methods In this multicenter study, we retrospectively included consecutive UC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cffb7d754eb5a4a75892bacb4ceef6c4
https://u-picardie.hal.science/hal-04161046
https://u-picardie.hal.science/hal-04161046
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
J Tinoco da Silva Torres, P Ellul, S Vieujean, I Ordas, J Burisch, I Mocanu, D Duricova, I Rodríguez-Lago, A Buisson, A Goldis, V Hernandez, N Arebi, I Kaimakliotis, M Nachury, M Fumery, M Allocca, N Pedersen, B Barberio, S Shaji, A Guedes, R Ribeiro, R Ungaro, J Lambert, J F Colombel
Publikováno v:
Journal of Crohn's and Colitis. 17:i443-i444
Background CD is classically seen as a progressive disease leading to bowel damage and disability. Disability has been proposed by the Spirit-IOIBD consensus1 as an endpoint in disease modification trials. However, there is a paucity of data regardin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::302e4e8028250c73ebf281eb7b39b10a
https://doi.org/10.1093/ecco-jcc/jjac190.0429
https://doi.org/10.1093/ecco-jcc/jjac190.0429
Autor:
N Mathieu, P Riviere, F Heluwaert, X Hébuterne, A Chupin, G Bouguen, L Vuitton, M Allez, C Montuclard, M Nachury, S Nancey, B Amélie, C Gilletta, V Abitbol, R Altwegg, A de Maissin, L Plastaras, P Ah Soune, A Boureille, Y Bouhnik, P Seksik, E Chanteloup, S marion, M Uzzan, P Andrau, C Rouillon, Y Arondel, L Peyrin Biroulet, D Laharie
Publikováno v:
Journal of Crohn's and Colitis. 17:i533-i534
Background Subcutaneous infliximab (IFX-SC) was launched in France for the treatment of patients with inflammatory bowel disease (IBD) in 2021. Real-life and pharmacokinetic (PK) data after switching from intravenous infliximab (IFX-IV) to IFX-SC are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1536201d830f33b144b640c8777e5555
https://doi.org/10.1093/ecco-jcc/jjac190.0534
https://doi.org/10.1093/ecco-jcc/jjac190.0534
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
G Le Cosquer, C Gilletta, A Amiot, P Rivière, M Nachury, C Rouillon, Y Bouhnik, V Abitbol, S Nancey, M Fumery, G Savoye, A Biron, L Picon, L Peyrin-Biroulet, M Vidon, C Reenaers, M Simon, B Caron, M Serrero, R Altwegg, A Benezech, F Goutorbe, J F Rahier, L Beaugerie, A L Pelletier, L Caillo, D Laharie, F Poullenot
Publikováno v:
Journal of Crohn's and Colitis
Journal of Crohn's and Colitis, 2023, 17 (Supplement 1), pp.i572-i572. ⟨10.1093/ecco-jcc/jjac190.0573⟩
Journal of Crohn's and Colitis, 2023, 17 (Supplement 1), pp.i572-i572. ⟨10.1093/ecco-jcc/jjac190.0573⟩
Background Breast cancer is the most common malignancy observed in patients with inflammatory bowel diseases (IBD) unrelated to the disease or its treatment (Poullenot F et al. JCC 2022). The main aim of our study was to assess the risk of incident c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a58a414d1b5237c1930c6c7670ed2eb
https://doi.org/10.1093/ecco-jcc/jjac190.0573
https://doi.org/10.1093/ecco-jcc/jjac190.0573
Autor:
F Poullenot, A Amiot, M Nachury, S Viennot, R Altwegg, Y Bouhnik, V Abitbol, S Nancey, L Vuitton, L Peyrin-Biroulet, A Biron, M Fumery, L Picon, M Vidon, C Reenaers, M Serrero, G Savoye, L Beaugerie, P Rivière, D Laharie
Publikováno v:
Journal of Crohn's and Colitis
Journal of Crohn's and Colitis, 2022, 16 (10), pp.1523-1530. ⟨10.1093/ecco-jcc/jjac061⟩
Journal of Crohn's and Colitis, 2022, 16 (10), pp.1523-1530. ⟨10.1093/ecco-jcc/jjac061⟩
Introduction Knowledge about the cancer risk when initiating a biologic in inflammatory bowel disease [IBD] patients with prior malignancy remains scarce, especially for vedolizumab. Our aim was to evaluate the rate of incident cancer in a cohort of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17f22cc6a4e0b0eee459214fd8327e50
https://pubmed.ncbi.nlm.nih.gov/35512337
https://pubmed.ncbi.nlm.nih.gov/35512337
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
G Malamut, M Simon, M Nachury, M Uzzan, M Serrero, M Fumery, C Trang-Poisson, C Zallot, V Abitbol, F Charbit-Henrion, J M Gornet, C Picard, N Cerf-Bensussan, S Chaussade, H Sokol
Publikováno v:
Journal of Crohn's and Colitis. 16:i223-i224
Background Inflammatory bowel diseases (IBD) associated with primary immunodeficiency (PID) remain poorly known. We aimed to isolate characteristics of IBD associated with PID. Methods Using a GETAID register, we reviewed medical files of recorded pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::511915a118676c49454232ab1166564f
https://doi.org/10.1093/ecco-jcc/jjab232.270
https://doi.org/10.1093/ecco-jcc/jjab232.270